Clinical Trial: De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303686) titled 'De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis' on Oct. 02.

Brief Summary: The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST).

The main question it aims to answer is:

Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflamma...